Should healthy people take an Alzheimer’s blood test? Clinical guidelines say no. But Quest Diagnostics, one of America’s largest medical diagnostic companies, seemed to…
When people experience concerning memory problems — losing their keys more often, forgetting important events, or struggling to find the right word in the…
Researchers in China taught village health providers how to prescribe blood pressure medication. Despite not being doctors, this intervention lowered blood pressure and dementia…
After being rejected by EU regulators but approved in the U.S., UK, and several Middle Eastern countries, Alzheimer’s drug Kisunla added a new market:…
Everyone with Alzheimer’s disease has beta-amyloid plaques and tau tangles in their brain. But despite advances across blood tests, cerebrospinal fluid tests, and brain…
This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
Fujirebio’s new blood test for Alzheimer’s biomarkers is the first to receive FDA approval, opening the door to Medicare coverage. Here’s what it can…
Common viral infections may make the brain more susceptible to dementia and other neurological diseases. For instance, the Epstein-Barr virus — which causes mononucleosis…
At first, scientists had no idea what might cause Alzheimer’s disease and had no underlying protein or pathway to target with treatments. Then came…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
Anti-amyloid drugs like Leqembi and Kisunla are among the first FDA-approved treatments for early-stage Alzheimer’s disease. But these breakthroughs come with a tradeoff: Up…
More than a decade ago, Alzheimer’s vaccines appeared in clinical trials — but failed. Now several companies are gearing up to test the next…
Scientists developed new brain cells to replace those lost in Parkinson’s. Early trials showed they’re safe — now, larger human trials are on the…
People with Down syndrome have a 9/10 chance of developing early-onset Alzheimer’s — a reality tied to genetics. This genetic condition also makes this…
In July 2024, European regulators rejected Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. By November, they had changed their minds. Now, the…